Dexamethasone induces caveolin-1 in vascular endothelial cells: Implications for attenuated responses to VEGF

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 8, 2013, Pages

  Igarashi, Junsuke ^a   Hashimoto, Takeshi ^a   Shoji, Kazuyo ^a   Yoneda, Kozo ^a   Tsukamoto, Ikuko ^a   Moriue, Tetsuya ^a   Kubota, Yasuo ^a   Kosaka, Hiroaki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Endothelial function; Growth factors; Receptors; Signal transduction

Indexed keywords

ALDOSTERONE; CAVEOLIN 1; DEXAMETHASONE; ESTRADIOL; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PROGESTERONE; PROTEIN KINASE B; RAC1 PROTEIN; TESTOSTERONE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; COW; DRUG MECHANISM; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; LUNG ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CATTLE; CAVEOLIN 1; CELLS, CULTURED; DEXAMETHASONE; ENDOTHELIAL CELLS; HUMANS; MALE; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

BOVINAE; RATTUS;

EID: 84878637836     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00268.2012     Document Type: Article

References (41)

1. Akaza I, Yoshimoto T, Tsuchiya K, Hirata Y. Endothelial dysfunction associated with hypercortisolism is reversible in Cushing's syndrome. Endocr J 57: 245-252, 2010.
2. Barar J, Campbell L, Hollins AJ, Thomas NP, Smith MW, Morris CJ, Gumbleton M. Cell selective glucocorticoid induction of caveolin-1 and caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochem Biophys Res Commun 359: 360-366, 2007.
3. Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R, Huang Y, Giordano F, Stan RV, Sessa WC. Endothelial-specific expression of caveolin-1 impairs micro vascular permeability and angiogen-esis. Proc Natl Acad Sei USA 102: 204-209, 2005.
4. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Durmus I, Korkmaz L, Celik S. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's syndrome. Endocrine 31: 300-304, 2007.
5. Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH, Winkler H. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J. Biol Chem 271: 19612-19616, 1996.
6. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteron-ism after treatment. Arch Intern Med 168: 80-85, 2008.
7. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341-1379, 2004.
8. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide syn-thase activation through a decrease in caveolin abundance. Circulation 103: 113-118, 2001.
9. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 17: 6633-6648, 1998.
10. Gill GN, Ill CR, Simonian MH. Angiotensin stimulation of bovine adrenocortical cell growth. Proc Natl Acad Sei USA 74: 5569-5573, 1977.
11. Gonzalez E, Kou R, Michel T. Racl modulates sphingosine 1 -phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. J Biol Chem 281: 3210-3216, 2006.
12. Gonzalez E, Nagiel A, Lin AJ, Golan DE, Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem 279: 40659-40669, 2004.
13. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Cortico-steroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 362: 1005-1013, 2010.
14. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. Statins induce S1P(1) receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 150: 470-479, 2007.
15. Igarashi J, Shoji K, Hashimoto T, Moriue T, Yoneda K, Takamura T, Yamashita T, Kubota Y, Kosaka H. Transforming growth factor-betal downregulates caveolin-1 expression and enhances sphingosine 1-phosphate signaling in cultured vascular endothelial cells. Am J Physiol Cell Physiol 297: C1263-C1274, 2009.
16. Kasselman LJ, Kintner J, Sideris A, Pasnikowski E, Krellman JW, Shah S, Rudge JS, Yancopoulos GD, Wiegand SJ, Croll SD. Dexa-methasone treatment and ICAM-1 deficiency impair VEGF-induced an-giogenesis in adult brain. J. Vase Res 44: 283-291, 2007.
17. Kim KH, Moriarty K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 73: 864-869, 2008.
18. Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. J Endocrinol Invest 31: 400-405, 2008.
19. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 14: 334-347, 2003.
20. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189-197, 2007.
21. Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells: evidence for an AMPK -> Racl -> Akt -> endothelial nitric-oxide synthase pathway. J. Biol Chem 282: 20351-20364, 2007.
22. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386-4392, 2001.
23. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angio-genesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem 274: 15781-15785, 1999.
24. Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol 1: 369-375, 1999.
25. Luo JC, Shin VY, Liu ES, Ye YN, Wu WK, So WH, Chang FY, Cho CH. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 485: 275-281, 2004.
26. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 61: 768-777, 2004.
27. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 100: 2146-2152, 1997.
28. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48: 165-171, 2006.
29. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
30. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxi-col 48: 359-391, 2008.
31. Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galig-niana MD, Vedoy CG, Schillaci R, Charreau EH, Sogayar MC, Elizalde PV. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 25: 7723-7739, 2006.
32. Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Mastiek CC, Lodish HF. Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J. Cell Biol 127: 1233-1243, 1994.
33. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271: 9690-9697, 1996.
34. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Gregoire V, Dessy C, Balligand JL, Feron O. Caveolin-1 expression is critical for vascular endothelial growth factor-induced isch-emic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 95: 154-161, 2004.
35. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin Endocrinol Metab 87: 4872-4878, 2002.
36. Tsukamoto I, Sakakibara N, Maruyama T, Igarashi J, Kosaka H, Kubota Y, Tokuda M, Ashino H, Hattori K, Tanaka S, Kawata M, Konishi R. A novel nucleic acid analogue shows strong angiogenic activity. Biochem Biophys Res Commun 399: 699-704, 2010.
37. van Batenburg MF, Li H, Polman JA, Lachize S, Datson NA, Busse-maker HJ, Meijer OC. Paired hormone response elements predict caveolin-1 as a glucocorticoid target gene. PLos One 5: e8839, 2010.
38. Wallerath T, Godecke A, Molojavyi A, Li H, Schrader J, Forstermann U. Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene. Nitric Oxide 10: 36-41, 2004.
39. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sei USA 96: 13357-13362, 1999.
40. Walters EH, Reid D, Soltani A, Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases? Pharmacol Ther 118: 128-137, 2008.
41. Yoneda K, Fujimoto T, Imamura S, Ogawa K. Distribution of fodrin in the keratinocyte in vivo and in vitro. J. Invest Dermatol 94: 724-729, 1990.